Clinical bottom line
Current evidence does not support the routine use of low-dose methotrexate for primary prevention of cardiovascular disease (CVD) in general practice. While methotrexate is well established as an anti-inflammatory agent in rheumatologic conditions, its role in cardiovascular prevention remains investigational and unproven. Recent appraisals highlight the lack of consistent benefit in reducing cardiovascular events outside specific inflammatory disease populations. Clinicians should continue to rely on established preventive strategies, including lifestyle modification and evidence-based pharmacotherapies, while awaiting further data on methotrexate’s cardiovascular effects.
What the evidence shows
Methotrexate, a folate antagonist with anti-inflammatory properties, has been hypothesized to reduce cardiovascular risk by modulating chronic vascular inflammation, a key driver of atherosclerosis. This rationale emerged from observational studies suggesting lower cardiovascular event rates in patients with rheumatoid arthritis treated with methotrexate. However, the direct evidence supporting methotrexate for cardiovascular prevention in the general population remains limited.
A recent comprehensive review by Mangoni et al. (2023) critically appraised the current evidence on methotrexate’s cardiovascular effects. The authors noted that randomized controlled trials (RCTs) specifically designed to assess methotrexate for cardiovascular prevention have yielded neutral or inconclusive results. For example, the Cardiovascular Inflammation Reduction Trial (CIRT), although not cited here due to source restrictions, found no significant reduction in major cardiovascular events with low-dose methotrexate compared to placebo in patients with prior coronary disease and either diabetes or metabolic syndrome.
In contrast, low-dose aspirin has a more established, albeit nuanced, role in cardiovascular prevention. Earlier studies such as those by Dagenais et al. (2001) and Ridker et al. (2005) demonstrated some benefit of aspirin in primary prevention, but more recent guidance, including the US Preventive Services Task Force recommendations summarized by Mahase et al. (2021), advises against routine aspirin use for primary prevention due to bleeding risks outweighing benefits in many patients. These findings underscore the challenges in balancing risk and benefit in preventive pharmacotherapy.
Methotrexate’s cardiovascular effects remain less well characterized than aspirin’s, and current evidence does not support its use outside clinical trials or specific inflammatory conditions. The anti-inflammatory hypothesis remains biologically plausible but unproven in broad primary prevention.
Caveats and uncertainty
Several important caveats limit the interpretation and application of current data on methotrexate for cardiovascular prevention:
- Most evidence derives from populations with inflammatory diseases (e.g., rheumatoid arthritis), which may not generalize to the broader primary prevention population.
- Large RCTs specifically targeting cardiovascular endpoints in non-inflammatory populations are scarce or have shown neutral results.
- Methotrexate’s safety profile includes potential hepatotoxicity, bone marrow suppression, and other adverse effects that require careful monitoring, limiting its appeal as a preventive agent in otherwise healthy individuals.
- The optimal dosing, duration, and patient selection criteria for methotrexate in cardiovascular prevention remain undefined.
- Established preventive measures, including blood pressure control, lipid management, smoking cessation, and lifestyle modification, have stronger evidence bases and favorable risk-benefit profiles.
How this may change practice
At present, low-dose methotrexate should not be incorporated into routine cardiovascular disease prevention strategies in primary care. Clinicians should continue to prioritize guideline-recommended interventions with proven efficacy and safety.
Methotrexate may remain relevant for cardiovascular risk reduction in patients with inflammatory conditions already receiving the drug for rheumatologic indications, but its use solely for cardiovascular prevention is not supported by current evidence.
Ongoing and future trials may clarify methotrexate’s role, particularly in patient subsets with heightened inflammatory risk profiles. Until then, methotrexate use for cardiovascular prevention should be considered experimental and confined to research settings.